Drugs / Flu mRNA (Formulation B3)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07204964 | Oct 2025 → Jul 2026 overdue | influenza | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Flu mRNA (Formulation B3) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07204964 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-based multivalent seasonal influenza vaccine candidates” NCT07204964 ↗ |
| Route | Intramuscular | “received intramuscularly” NCT07204964 ↗ |